Trial Profile
A Clinical Phase II Trial to Describe Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of Spectrila With the Pharmaceutical Active Ingredient Recombinant L-Asparaginase in Adult Subjects With Newly Diagnosed Acute B-Cell Lymphoblastic Leukaemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2022
Price :
$35
*
At a glance
- Drugs Recombinant L-Asparaginase-medac (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Medac
- 09 May 2022 Planned End Date changed from 1 Apr 2023 to 1 May 2026.
- 09 May 2022 Planned primary completion date changed from 1 Mar 2022 to 1 May 2025.
- 21 Aug 2020 Planned End Date changed from 31 Jul 2022 to 1 Apr 2023.